ROCHESTER MEDICAL CORPORATION 
By STEWARTVILLE, Minn., April 24, 2012 /PRNewswire/ -- Rochester Medical Corporation (NASDAQ:ROCM) today announced operating results for its second quarter ended March 31, 2012.
The Company reported record sales of $15,259,000 for the current quarter compared to $12,853,000 for the second quarter of last year. It also reported net income of $603,000 or $0.05 per diluted share compared to net loss of ($1,259,000) or ($0.10) per diluted share for the same quarter of last year.
The approximate 19% increase in sales (20% on a constant currency basis) resulted from a 17% increase in Rochester Medical Direct Sales (20% on a constant currency basis) and a 24% increase in Private Label Sales (24% on a constant currency basis). Direct Sales include sales made directly to the end consumer and include all Rochester branded sales, U.K. Script Easy sales, and all Laprolan sales. Constant currency basis assumes current exchange rates for all periods in order to exclude the impact of foreign exchange variations. In the second quarter of fiscal 2012, the U.S. dollar was somewhat stronger versus the pound sterling and the Euro, thus negatively affecting Rochester Medical Direct Sales growth levels in actual U.S. dollars given the significant volume of direct sales in the United Kingdom and The Netherlands.
Net income adjusted for certain non-recurring unusual items and certain recurring non-cash expenses, or "Non-GAAP Net Income" for the current quarter was $920,000 or $0.08 per diluted share compared to Non-GAAP Net Loss of ($437,000) or ($0.04) per diluted share for the second quarter of last year. The increase for the current quarter is primarily due to increased gross profits as a result of increased sales.
Commenting on the second quarter results, Rochester Medical's CEO and President Anthony J. Conway said, "We are very pleased with our recent progress. Our Direct Sales are strengthening nicely. Overall U.S. Direct Sales rose 32% over last year's second quarter with U.S. Home Care sales growing at a strong 39% pace and U.S. Acute Care sales rising 15%. These numbers continue to reflect the increasing effectiveness of our U.S. Sales and Marketing team and the increasing acceptance of our advanced catheter technologies. The United Kingdom also reported solid constant currency growth of 18%. Laprolan sales declined 11% year-over-year in constant currency, however we expect improving sales going forward driven by recent investments to strengthen the Sales and Management team in that part of our organization. International Direct Sales outside of the U.K. and the markets served by Laprolan were very strong this quarter, increasing 69% year-over-year. Private Label sales showed strong growth of 24%, but as we have previously noted, these sales can fluctuate significantly from quarter to quarter due to the timing of orders."
Conference Call and Webcast
The Company will hold a quarterly conference call today to discuss its earnings report. The call will begin at 3:30 p.m. central time (4:30 p.m. eastern time).
This call is being webcast by Thomson Reuters and can be accessed at Rochester Medical's website at www.rocm.com. To listen live to the conference call via telephone, call:
Domestic: 888 680.0892
International: 617 213.4858
Pass code: 76674231
Preregistration:
https://www.theconferencingservice.com/prereg/key.process?key=P77FPAVK9
Replay will be available for seven days at www.rocm.com or via telephone at:
Domestic: 888 286.8010
International: 617 801.6888
Pass code: 54644869
Individual investors can listen to the call at www.fulldisclosure.com, Thomson Reuters individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (www.streetevents.com).
Forward-Looking Statements
This press release contains "forward-looking statements" with the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the future financial and operating results of Rochester Medical. Such statements are based on currently available information, operating plans and management's expectations about future events and trends. Such statements inherently involve significant risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the uncertainty of estimated revenues and profits, the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for the Company's products and increased volatility in foreign exchange rates, the uncertainty of market acceptance of new product introductions, and our level of success in increasing Rochester Medical Direct Sales revenue, the uncertainty of gaining new strategic relationships or locating and capitalizing on strategic opportunities, the uncertainty of timing of Private Label Sales revenues (particularly international customers), FDA and other regulatory review and response times, and other risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2011, and reports on Forms 10-Q and 8-K. Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Use of Non-GAAP Financial Measures
Rochester Medical has provided Non-GAAP Net Income (Loss) in addition to net income (loss) calculated in accordance with generally accepted accounting principles (GAAP) because management believes Non-GAAP Net Income (Loss) provides a more consistent basis for comparisons that are not influenced by certain charges and non-cash expenses and are therefore helpful in understanding Rochester Medical's underlying operating results. Similarly, constant currency represents reported sales with the cost/benefit of currency movements removed. Management uses the measure to understand the growth of the business on a constant dollar basis, as fluctuations in exchange rates can distort the underlying growth of the business both positively and negatively. While we recognize that foreign exchange volatility is a reality for a global company, we routinely review our Company performance on a constant dollar basis, and we believe this also allows our shareholders to understand better our Company's growth trends.
Non-GAAP Net Income (Loss) and constant currency are not measures of financial performance under GAAP, and should not be considered an alternative to net income or any other measure of performance or liquidity under GAAP. Non-GAAP Net Income (Loss) and constant currency are not comparable to information provided by other companies. Non-GAAP Net Income (Loss) and constant currency have limitations as analytical tools and should not be considered in isolation or as a substitution for analysis of our results as reported under GAAP. Reconciliations of Net Loss and Non-GAAP Net Income (Loss), and reconciliations of sales under GAAP and sales on a constant currency basis, are presented at the end of this press release.
About Rochester Medical Corporation
Rochester Medical Corporation develops, manufactures, and markets disposable medical catheters and devices for urological and continence care applications. The Company also sells certain ostomy and wound and scar care products and other brands of urological products into the European marketplace.
For further information, please contact Anthony J. Conway, President and Chief Executive Officer or David A. Jonas, Chief Financial Officer of Rochester Medical Corporation at (507) 533-9600 or Parice Halbert, CFA, at Westwicke Partners (443) 213-0500. More information about Rochester Medical is available on its website at http://www.rocm.com.
ROCHESTER MEDICAL CORPORATION
Reconciliation of Reported GAAP Revenue to Non-GAAP Revenue in Constant Currency
For the Three and Six months
ended
March 31, 2012 and 2011
(unaudited) (unaudited)
Three months ended Six months ended
March 31, March 31,
--------- ---------
2012 2011 2012 2011
---- ---- ---- ----
GAAP Sales as Reported $15,258,611 $12,852,601 $29,104,277 $23,799,006
=========== =========== =========== ===========
British Sterling Exchange rate
as Reported 1.57 1.60 1.57 1.59
==== ==== ==== ====
Euro Exchange rate as Reported 1.31 1.37
==== ====
Constant Currency Sales $15,258,611 $12,671,515 $29,104,277 $23,595,089
=========== =========== =========== ===========
(1) Exchange rate used for
Constant Currency Purposes 1.57 1.57 1.57 1.57
==== ==== ==== ====
(2) Exchange rate used for
Constant Currency Purposes 1.31 1.31 1.31 1.31
==== ==== ==== ====
Net Effect of Constant
Currency Illustration -
British Sterling $ - $(84,522) $ - $(107,353)
Net Effect of Constant
Currency Illustration -Euros $ - $(96,564) $ - $(96,564)
===================== ======== ===================== ========
Total Net Effect of Constant
Currency Illustration $ - $(181,086) $ - $(203,917)
===================== ========= ===================== =========
(1) For illustrative purposes constant currency translates prior period foreign sales at current exchange rates.
For Rochester Medical Corporation this is the conversion rate of British pounds to US dollars. The rate represents the
average exchange rate for the respective three or six month period.
(2) For illustrative purposes constant currency translates prior period foreign sales at current exchange rates.
For Rochester Medical Corporation this is the conversion rate of Euros to US dollars. The rate represents the
average exchange rate for the respective three or six month period. The six month rate is the same as the three month
rate as the acquisition of Laprolan was effective January 1, 2011.
ROCHESTER MEDICAL CORPORATION
Reconciliation of Reported GAAP Net Income to Non-GAAP Net Income
For the Three and Six months
ended
March 31, 2012 and 2011
(unaudited) (unaudited)
Three months ended Six months ended
March 31, March 31,
--------- ---------
2012 2011 2012 2011
---- ---- ---- ----
GAAP Net Income (Loss) as
Reported $603,000 $(1,259,000) $527,000 $(1,428,000)
======== =========== ======== ===========
Diluted EPS as Reported $0.05 $(0.10) $0.04 $(0.12)
===== ====== ===== ======
Adjustments for non-recurring
unusual items:
Merger and acquisition costs
for Laprolan (1) 255,000 391,000
------- -------
Subtotal - 255,000 - 391,000
Adjustments for recurring non-
cash expenses:
Intangible amortization (2) 158,000 195,000 316,000 323,000
ASC 718 compensation expense
(3) 159,000 372,000 361,000 567,000
------- ------- ------- -------
Subtotal 317,000 567,000 677,000 890,000
------- ------- ------- -------
Non-GAAP Net Income $920,000 $(437,000) $1,204,000 $(147,000)
======== ========= ========== =========
Non-GAAP Diluted EPS $0.08 $(0.04) $0.10 $(0.01)
===== ====== ===== ======
Weighted Average Shares -
Diluted 12,235,701 12,223,347 12,258,402 12,174,780
(1) Merger and acquisition costs related to the purchase of Laprolan B.V. from Fornix N.V.
(2) Amortization of the intangibles acquired in June 2006 asset acquisition from Coloplast AS and Mentor
Corporation and the intangibles acquired in the January 2011 acquisition of Laprolan from Fornix N.V.
Management believes these assets are appreciating. This adjustment adds back amortization
expense for the three and six months ended March 31, 2012 and 2011 related to certain intangibles.
The gross amount of amortization expense for the three months ended March 31, 2012 and 2011 is
$218,000 and $251,000 net of taxes of $60,000 and $56,000 for net amounts of $158,000 and $195,000
respectively. The gross amount of amortization expense for the six months ended March 31, 2012 and 2011
is $436,000 and $414,000 net of taxes of $120,000 and $91,000 for net amounts of $316,000 and $323,000
respectively.
(3) Compensation expense mandated by ASC 718. This adjustment adds back the compensation expense
recorded for stock options granted to employees and directors that vested during the three and six months ended
March 31, 2012 and 2011. The gross amount of compensation expense for the three months ended March 31, 2012
and 2011 is $248,000 and $582,000 net of taxes of $89,000 and $210,000 for net amounts of $159,000 and
$372,000 respectively. The gross amount of compensation expense for the six months ended March 31, 2012
and 2011 is $564,000 and $877,000 net of taxes of $203,000 and $310,000 for net amounts of $361,000 and
$567,000 respectively.
ROCHESTER MEDICAL CORPORATION
Press Release - F12 Second Quarter
Summary Statements Of Operations
(unaudited) (unaudited)
Three months ended Six months ended
March 31, March 31,
--------- ---------
2012 2011 2012 2011
---- ---- ---- ----
Sales $15,258,611 $12,852,601 $29,104,277 $23,799,006
Cost of sales 7,828,875 6,493,407 14,706,068 12,035,681
--------- --------- ---------- ----------
Gross profit 7,429,736 6,359,194 14,398,209 11,763,325
Gross
profit
% 48.7% 49.5% 49.5% 49.4%
Costs and expenses:
Marketing
and selling 4,219,492 5,012,747 8,723,612 8,894,727
Research and
development 247,889 251,672 624,158 529,527
General and
administrative 2,128,024 2,403,698 4,236,837 4,112,791
--------------
Total operating expenses 6,595,405 7,668,117 13,584,607 13,537,045
--------- --------- ---------- ----------
Income (loss) from operations 834,331 (1,308,923) 813,602 (1,773,720)
Other income (expense)
Interest
income 9,465 51,977 19,200 104,547
Interest
expense (8,395) (123,596) (89,545) (154,855)
Other
income 48,712 (12,865) 29,057 (29,147)
Net income (loss) before income taxes 884,113 (1,393,407) 772,314 (1,853,175)
Income tax expense(benefit) 281,599 (134,009) 245,147 (424,695)
------- -------- ------- --------
Net income (loss) $602,514 $(1,259,398) $527,167 $(1,428,480)
======== =========== ======== ===========
Earnings (loss) per common share - Basic $0.05 $(0.10) $0.04 $(0.12)
===== ====== ===== ======
Earnings (loss) per common share - Diluted $0.05 $(0.10) $0.04 $(0.12)
===== ====== ===== ======
Weighted Average Shares: 12,003,167 12,223,347 12,049,900 12,174,780
========== ========== ========== ==========
Basic
Weighted Average Shares:
Diluted 12,235,701 12,223,347 12,258,402 12,174,780
Rochester Medical Corporation
Press Release - F12 Second Quarter
Condensed Balance Sheets
(unaudited)
March 31, September 30,
2012 2011
---- ----
Assets
Current Assets
Cash and
equivalents $8,813,309 $8,722,935
Marketable
securities 6,810,597 26,182,308
Accounts
receivable 9,931,708 8,644,332
Inventories 11,367,361 11,278,694
Prepaid expenses
and other
assets 1,607,363 1,361,259
Deferred
income tax
asset 2,036,493 1,618,495
--------- ---------
Total current assets 40,566,831 57,808,023
Property and
equipment, net 12,181,449 12,052,685
Deferred income
tax asset 1,180,015 1,242,010
Intangible assets,
net 10,040,656 10,272,671
Goodwill 9,859,132 9,764,075
Total Assets $73,828,083 $91,139,464
Liabilities and Stockholders' Equity
Current
liabilities:
Accounts
payable $2,580,460 $2,773,398
Accrued
expenses 2,698,674 2,961,270
Short-term
debt - 17,862,185
--- ----------
Total current
liabilities 5,279,134 23,596,853
Long-term
liabilities 1,931,143 1,565,764
Stockholders'
equity 66,617,806 65,976,847
Total Liabilities and
Stockholder Equity $73,828,083 $91,139,464
SOURCE Rochester Medical Corporation
